Patents by Inventor Jonathan A. Hickson

Jonathan A. Hickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11045480
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 29, 2021
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Publication number: 20200255508
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Application
    Filed: September 19, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Publication number: 20190105329
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 11, 2019
    Inventors: Kurt C. GISH, Jonathan A. HICKSON, Susan Elizabeth MORGAN-LAPPE, James W. PURCELL
  • Publication number: 20190105328
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 11, 2019
    Inventors: Kurt C. GISH, Jonathan A. HICKSON, Susan Elizabeth MORGAN-LAPPE, James W. PURCELL
  • Publication number: 20190099431
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 4, 2019
    Inventors: Kurt C. GISH, Jonathan A. HICKSON, Susan Elizabeth MORGAN-LAPPE, James W. PURCELL
  • Patent number: 10195209
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 5, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Publication number: 20190031783
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 31, 2019
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Patent number: 10188660
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 29, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Publication number: 20180371071
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Application
    Filed: April 28, 2017
    Publication date: December 27, 2018
    Applicant: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Patent number: 9944720
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 17, 2018
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Publication number: 20170151343
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: November 29, 2016
    Publication date: June 1, 2017
    Inventors: Kurt C. GISH, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Publication number: 20170151344
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: November 29, 2016
    Publication date: June 1, 2017
    Inventors: Kurt C. GISH, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Patent number: 9469688
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Publication number: 20160122439
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: September 4, 2015
    Publication date: May 5, 2016
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Publication number: 20160060332
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Application
    Filed: August 10, 2015
    Publication date: March 3, 2016
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Patent number: 9163093
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Patent number: 9132190
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 15, 2015
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Patent number: 9045551
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Publication number: 20140348835
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: June 11, 2014
    Publication date: November 27, 2014
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Publication number: 20140134172
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 15, 2014
    Applicant: ABBVIE INC.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao